Porton Pharma Solutions Ltd. Class A

Porton Pharma Solutions Ltd. Class A

SSZSE:300363
21.72
CNY
+0.07
(+0.32%)
-0.28EPS
13.35BMarket Cap
Mar 22Next Earn

Total Valuation

CNY

As of September 30, 2026, Porton Pharma Solutions Ltd. Class A carries a market capitalization of 13.35B, placing it among publicly traded companies globally. Its enterprise value stands at 13.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap13.35B
Enterprise Value13.42B

Important Dates

Porton Pharma Solutions Ltd. Class A's next confirmed earnings release is scheduled for March 22, 2027.

Earnings Date3/22/2027

Share Statistics

As of September 30, 2026, Porton Pharma Solutions Ltd. Class A has 543.44M shares outstanding.

Shares Outstanding543.44M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.66, and the price-to-book ratio stands at 2.64.

PS Ratio3.66
PB Ratio2.64
P/TBV Ratio2.96

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.42B versus a market cap of 13.35B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.69

Financial Position

As of September 30, 2026, Porton Pharma Solutions Ltd. Class A maintains a current ratio of 2.01, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.51, indicating elevated leverage, while an interest coverage ratio of -2.03 demonstrates limited ability to service its debt obligations.

Current Ratio2.01
Quick Ratio0.76
Debt / Equity24.51
Debt / EBITDA-17.05
Interest Coverage-2.03

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Porton Pharma Solutions Ltd. Class A posted a negative return on equity (ROE) of -1.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.14, reflecting losses generated across the asset base. The company generates approximately 835,076.55 in revenue per employee across its workforce of 4,359.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.94 indicates how many times Porton Pharma Solutions Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-1.85
Return on Assets (ROA)-1.14
Revenue Per Employee835,076.55
Employee Count4,359.00
Inventory Turnover2.94

Taxes

CNY

Over the twelve months ended September 30, 2026, Porton Pharma Solutions Ltd. Class A recorded 70.32M in income tax expense. The company reported a pretax loss of -80.91M and -95.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax70.32M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Porton Pharma Solutions Ltd. Class A's stock has declined approximately 11.09% over the past 52 weeks. The 50-day moving average sits at 22.24, while the 200-day moving average is 20.24.

52-Week Price Change-11.09%
50-Day Moving Average22.24
200-Day Moving Average20.24

Income Statement

CNY

Over the twelve months ended September 30, 2026, Porton Pharma Solutions Ltd. Class A generated 3.64B in revenue and converted that into -95.72M in net income, yielding earnings per share of -0.28. EBITDA reached -74.06M, while operating income came in at 338.09M.

Revenue3.64B
Gross Profit1.22B
Operating Income338.09M
Pretax Income-80.91M
Net Income-95.72M
EBITDA-74.06M
EBIT-74.06M
Earnings Per Share (EPS)-0.28

Balance Sheet

CNY

As of September 30, 2026, Porton Pharma Solutions Ltd. Class A holds 1.29B in cash and equivalents against 1.26B in total debt, resulting in a net debt position of -511.92M. Total book value stands at 5.05B, with working capital of 1.70B providing operational flexibility.

Cash & Cash Equivalents1.29B
Total Debt1.26B
Net Debt-511.92M
Equity (Book Value)5.05B
Book Value Per Share9.29
Working Capital1.70B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-114.96M

Margins

Over the twelve months ended September 30, 2026, Porton Pharma Solutions Ltd. Class A posted a gross margin of 33.43, reflecting its pricing power and cost economics. The operating margin of 9.29 and net profit margin of -2.63 provide insight into operational efficiency.

Gross Margin33.43
Operating Margin9.29
Pretax Margin-2.22
Profit Margin-2.63
EBITDA Margin-2.03

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Porton Pharma Solutions Ltd. Class A paid dividends of 0.12 per share. The dividend payout ratio of -32.37 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Porton Pharma Solutions Ltd. Class A shareholders.

Dividend Per Share0.12
Payout Ratio-32.37
Shareholder Yield4.95

Stock Splits

Porton Pharma Solutions Ltd. Class A's most recent stock split took place on September 29, 2015 with a 2:3 split ratio.

Last Split Date9/29/2015
Split Ratio2:3

Scores

As of September 30, 2026, Porton Pharma Solutions Ltd. Class A has an Altman Z-Score of 4.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.15